

Applicant Initiated Interview Request FormApplication No.: 10/572,582First Named Applicant: Bellur S. PrabhakarExaminer: HIBBERT, CATHERINE S.Art Unit: 1636Status of Application: AFTER FINAL**Tentative Participants:**(1) Alice O. Martin(2) Bellur S. Prabhakar(3) Catherine S. Hibbert(4) Christopher LowProposed Date of Interview: 08/31/2010Proposed Time: 11:00 (AM/PM)**Type of Interview Requested:**(1) ☒ Telephonic (2) ☐ Personal (3) ☐ Video Conference

** Call-in Number: 1-888-857-3844 - Passcode 214-831-6165

Exhibit To Be Shown or Demonstrated: ☐ YES☒ NO

If yes, provide brief description: _____

Issues To Be Discussed

Issues (Rej., Obj., etc)	Claims/ Fig. #s	Prior Art	Discussed	Agreed	Not Agreed
(1) <u>Rej. 103</u>	<u>21, 25, 27</u>	<u>(see attached Annex)</u>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(2) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(3) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(4) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Continuation Sheet Attached☐ Proposed Amendment or Arguments AttachedBrief Description of Arguments to be Presented: Publications cited to support 103 report MADD/DENN without knowledge of isoforms as presently claimed could not develop cancer therapeutics as claimed. Their teachings would lead to recipient's death.

An interview was conducted on the above-identified application on _____

NOTE: This form should be completed and filed by applicant in advance of the interview (see MPEP § 713.01). If this form is signed by a registered practitioner not of record, the Office will accept this as an indication that he or she is authorized to conduct an interview on behalf of the principal (37 CFR 1.32(a)(3)) pursuant to 37 CFR 1.34. This is not a power of attorney to any above named practitioner. See the Instruction Sheet for this form, which is incorporated by reference. By signing this form, applicant or practitioner is certifying that he or she has read the Instruction Sheet. After the interview is conducted, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible. This application will not be delayed from issue because of applicant's failure to submit a written record of this interview.



Applicant/Applicant's Representative Signature

Alice O. Martin

Typed/Printed Name of Applicant or Representative

35601

Registration Number, if applicable

Examiner/SPE Signature

This collection of information is required by 37 CFR 1.133. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 24 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ANNEX

In re Application of: Bellur S. Prabhakar

Atty. Docket No. 21726-103049

Application No. 10/572,582

Art References to be discussed at Interview

Al-Zoubi et al., "Contrasting Effects of IG20 and its Splice Isoforms, MADD and DENN-SV, on Tumor Necrosis Factor α -induced Apoptosis and Activation of Caspase-8 and -3," <i>Jrnl. of Biological Chem.</i> , 276:50 47202-47211 (2001).
Efimova et al., "Differential Effects of IG20 and Its Splice Isoform, DENN-SV, on Cell Proliferation and Apoptosis," <i>FASEB Jrnl.</i> , 16:5 A1083 (2002).
Lim & Chow, "Induction of Marked Apoptosis in Mammalian Cancer Cell Lines by Antisense DNA Treatment to Abolish Expression of DENN (Differently Expressed in Normal and Neoplastic Cells)," <i>Molecular Carcinogenesis</i> , 35: 110-126 (2002).
Thompson, "Applications of antisense and siRNAs during preclinical drug development," <i>Cancer Res.</i> , 7 (17): 7352-7361 (2002).